Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Uterine Cervical Neoplasms 18Prostatic Neoplasms 18Sarcoma 5Neoplasms 4Uterine Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer 1Retinoblastoma 1Prostate Cancer With Intermediate Risk 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Malignant Female Reproductive System Neoplasm 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation 1Endometrial Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Cholangiocarcinoma 1

Interventions

Cisplatin 24Carboplatin 19Paclitaxel 18pembrolizumab 12Gemcitabine 12Radiotherapy 9Fluorouracil 9Specimen Handling 8Magnetic Resonance Spectroscopy 7cemiplimab 6Platinum 6Nivolumab 6Docetaxel 6Cetuximab 61,2-diaminocyclohexaneplatinum II citrate 6epothilone B 5anlotinib 5Sunitinib 5Pemetrexed 5Oxaliplatin 5Everolimus 5Drug Therapy 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5durvalumab 4Radiotherapy, Intensity-Modulated 4Radiation 4Erlotinib Hydrochloride 4Celecoxib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma × Brachytherapy × Clear all
NCT01301612 2014-07-14

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Eurofarma Laboratorios S.A.

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡